Compare · BSX vs SIBN
BSX vs SIBN
Side-by-side comparison of Boston Scientific Corporation (BSX) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 71.7x SIBN ($892.3M).
- SIBN has been more active in the news (6 items in the past 4 weeks vs 4 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- Boston Scientific Corporation
- SI-BONE Inc.
- Price
- -
- -
- Market cap
- $63.97B
- $892.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 12
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest SIBN
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $378,160 worth of shares (20,000 units at $18.91) as part of a pre-agreed trading plan (SEC Form 4)
- SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
- Chief Executive Officer Francis Laura sold $522,596 worth of shares (25,972 units at $20.12) as part of a pre-agreed trading plan (SEC Form 4)